



MEDICAL ADVISORY BOARD

2027 Sponsorship Prospectus

About the Cholangiocarcinoma Foundation

The Cholangiocarcinoma Foundation's (CCF) mission is to find a cure and improve the quality of life for those affected by cholangiocarcinoma (CCA). Founded in 2006 in Salt Lake City, Utah, by a family who lost a loved one to the disease, CCF has grown into a global leader in patient support, education, advocacy, and funding basic, clinical, and translational research. CCF's core values are patients first, collaboration, innovation, and urgency.

About our Medical Advisory Boards

The Cholangiocarcinoma Foundation offers high-impact, 2-hour Medical Advisory Boards (MABs) designed to provide non-binding, expert insights to companies advancing therapies and technologies in the cholangiocarcinoma space. These sessions are facilitated through CCF's International Cholangiocarcinoma Research Network (ICRN), a global consortium of nearly 500 researchers and clinicians representing more than 230 institutions across 37 countries.

Each advisory panel is customized to meet the company's specific goals and objectives and may include medical oncologists, hepatologists, gastroenterologists, surgeons, interventional radiologists, pathologists, translational researchers, and other specialists with expertise in CCA. These discussions provide timely, disease-specific perspectives from internationally recognized leaders in cholangiocarcinoma research and clinical care, helping inform strategic decisions across the product development lifecycle.

Potential areas of discussion include:

- Clinical trial design and feasibility
- Real-world treatment insights
- Biomarker testing strategies
- Patient identification and referral pathways
- Recruitment and enrollment challenges
- Standard-of-care and treatment landscape considerations
- Regional and global perspectives
- Unmet needs and barriers to care
- Commercialization and market access considerations
- Emerging research trends and future opportunities in CCA

Medical Advisory Boards provide companies with direct access to leading experts actively shaping the future of cholangiocarcinoma research and patient care. The insights gained can help optimize development programs, strengthen clinical trial strategies, inform commercialization efforts, and ultimately improve patient access to innovative therapies.

Following each session, companies receive a comprehensive summary highlighting key themes, expert insights, and actionable recommendations discussed during the advisory board.

For more information, contact:

Kaylin Allenbrand, Director of Corporate Partnerships, kaylin.allenbrand@curecca.org

Meeting Format

Duration: 2 hours via Zoom or in-person
(can be adjusted -longer- if deemed necessary)

Participants: Approximately six ICRN investigators/
clinicians, selected based on company needs

Moderator: The sessions are confidential and collaborative, typically moderated by Dr. Juan Valle, CCF's Chief Medical Officer and an internationally recognized cholangiocarcinoma expert. An alternative moderator may be selected based on the topic, geographic region, or company preference to ensure the most relevant expertise.

Timeline: Planning and execution typically take 6-8 weeks from the time CCF receives the pledge.

Session Includes

- Pre-meeting coordination on goals, agenda, and participant criteria
- CCF Recruiting, contracting, and preparing participants
- Company-led presentation (if applicable)
- Prepared discussion questions and open dialogue
- Optional recording of meeting
- Post-event survey and report summarizing key findings
- Optional polling and post-meeting surveys
- Room rental, A/V and coordination, if in-person

2027 Patient Advisory Board Benefits

By participating in a Medical Advisory Board, your company will receive:

- **Tailored Scientific Input:** Access to cholangiocarcinoma experts selected for alignment with your clinical or research goals
- **Global Expertise:** Tap into CCF's ICRN, representing a broad geographic and institutional cross-section of thought leaders in CCA
- **Facilitation by Leading Experts:** Meeting moderated by Dr. Juan Valle, one of the world's foremost authorities in CCA, or alternative moderator of your choice
- **Full-Service Management** CCF handles all aspects of the meeting, including:
 - Recruitment and coordination of participants
 - Creation and distribution of agendas and briefing materials
 - Execution of confidentiality agreements and participant honoraria
 - Hosting and tech support (for virtual) or on-site coordination (for in-person)
 - Post-event survey and report summarizing key findings
 - Room rental, A/V equipment, etc., if in-person
- **Visibility and Relationship-Building:** Strengthen your company's reputation as a committed partner in rare cancer innovation through trusted collaboration with one of the field's most respected foundations.

Investment

The total investment for a virtual Medical Advisory Board is **\$70,000**. This fee includes hosting and facilitation, moderator engagement, material preparation, participant honoraria, travel and room rental (if applicable), plus coordination of all logistics and a post-meeting summary outlining key insights and takeaways. In-person sessions are available at a higher rate, with pricing based on variables such as venue rental, travel, catering, and on-site coordination. A customized quote will be provided based on location and session details.